GlassScriptPhysician profile
Sara K Grell
NPI 1669533931
$5,191.22
in general payments reported to CMS, 2019-2025
22 companies · $896 in 2025
The $896 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $129 · 2021: $472 · 2022: $523 · 2023: $509 · 2024: $1,365 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $926.63 | 2022-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Alcon Vision LLC | $658.22 | 2019-2025 | Precision 1, Tryptyr, Total30 |
| Johnson & Johnson Vision Care, INC. | $583.51 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $403.23 | 2019-2021 | |
| Abbvie INC. | $393.14 | 2022-2025 | |
| Astellas Pharma US INC | $367.02 | 2023-2025 | Izervay |
| Glaukos Corporation | $313.73 | 2021-2025 | |
| Coopervision INC. | $305.86 | 2019-2023 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $284.61 | 2019-2024 | |
| Apellis Pharmaceuticals, INC. | $238.16 | 2024 | Syfovre |
| Allergan, INC. | $176.04 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 | |
| Genzyme Corporation | $113.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.71 | 2020-2022 | |
| Optovue, INC. | $66.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $34.29 | 2021-2023 | Flarex |
| Tarsus Pharmaceuticals, INC. | $24.46 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $24.22 | 2021 | |
| Harrow Eye, LLC | $22.45 | 2025 | Vevye |
| Sight Sciences, INC. | $19.99 | 2020 | |
| Dompe US, INC. | $13.38 | 2022 | |
| Thea Pharma INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Grell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.